Plus: earlier insulin pump therapy for children; type 2 diabetes testing
Saturday, Dec. 5, 2020 : Issue #1086 TOP STORIES - Diabetes News & Research |
|
Letter from the Editor
I am not sure if you have seen all the Facebook ads for CGM devices for non-diabetes patients. One of the companies, January A.I., touts their device as a way to evaluate your food choices to maximize your metabolic rate and enhance your performance.
A better and cheaper way to accomplish this would be to read this week's feature from Dr. Sheri Colberg on how to determine what to eat to maximize your performance.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
| |
|
|
|
TOP STORIES - Diabetes News and Research |
|
| What You Eat and Drink Affects Your Exercise Performance
by Sheri Colberg, PhD
How well you perform (physically) when you exercise is impacted in a number of ways by the intake of macronutrients—that is, carbohydrate, fat, and protein—whether you have diabetes or not. Performance is directly affected by your calorie intake both during an activity and when you are recovering from it. |
| |
|
|
|
|
| Did You Know? Earlier Insulin Pump Therapy Has Benefits for Children with Type 1 Diabetes Using Multiple Injections
According to a new study, early initiation of insulin pump therapy in pediatric patients newly diagnosed with type 1 diabetes was associated with improved clinical outcomes. The study was based on data from 501 diabetes centers. They aimed to assess the efficacy and outcome of early therapy initiation versus delayed initiation post-diagnosis. "Although continuous subcutaneous insulin infusion therapy is associated with improved metabolic control compared with multiple daily insulin injections in children with type 1 diabetes, it is unclear when it is best to start it after diagnosis," the investigators wrote. Thus, included in their sample were 8332 patients diagnosed with type 1 diabetes between 2004-2014 and aged six months to 15 years old at diagnosis. They divided the sample into two cohorts — those who had initiated insulin pump therapy within the first six months of diabetes diagnosis (48.1%) and those who initiated treatment in the 2nd or 3rd year (51.9%). Outcomes parameters included the glycated hemoglobin (HbA1c) values, cardiovascular risk profile, rates of acute complications and hospitalizations associated with diabetes during the most recent year with insulin pump therapy. In both groups, the median duration of diabetes during follow-up was 6.7 years (IQR, 5.1-8.7 in the early cohort vs. 5.0-8.7 in the delayed cohort). Patients with early initiation of therapy demonstrated an overall mean HbA1c value of 7.8 A1c (62.6 mmol/mol) (95% CI 62.1-63.2)—in comparison with an A1c of 8% (64.1 mmol/mol) (95% CI; 63.6-64.6; P = .0006) for the delayed therapy cohort. Further, the early therapy cohort had lower rates of hypoglycemic coma (incidence rate [IR], 0.44 [95% CI, 0.24-0.79; P = .0064]) and hospitalization (IR, 0.86 [95% CI, 0.78-0.94; P = .0016]).
A better cardiovascular risk profile was observed in patients with early initiation of insulin pump therapy than in those with delayed initiation, including reduced blood pressure and non-HDL cholesterol. Overall, they concluded by emphasizing the clinical benefit associated with early initiation of insulin pump therapy for this patient population.
The study, "Early versus delayed insulin pump therapy in children with newly diagnosed type 1 diabetes: results from the multicentre, prospective diabetes follow-up DPV registry," was published online in The Lancet: Child and Adolescent Health. |
|
|
| Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters: Mia Flowers, PharmD. Candidate of Florida Agricultural & Mechanical University School of Pharmacy Shana Indawala, PharmD Candidate, University of South Florida Health, Taneja College of Pharmacy Arjay Mendoza, PharmD Candidate, University of Colorado Denver Skaggs School of Pharmacy and Pharmaceutical Sciences Destiny Reed, PharmD. Candidate, Florida A&M College of Pharmacy and Pharmaceutical Sciences |
|
|
|
|
|
| | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
